Xeris makes ready-to-use injectable drugs for rare hormone and nerve conditions, like a liquid glucagon pen for severe low blood sugar.
Money comes from selling three approved drugs—Gvoke, Keveyis, and Recorlev—with gross margins around 83% and recurring prescription revenue.
Its XeriSol/XeriJect tech enables stable liquid formulations competitors like Eli Lilly and Novo Nordisk haven't matched, but larger rivals with bigger sales forces could erode this niche advantage.
Key events, in time order
Post-earnings selloff corrected as stock fills gap, indicating one-time charge impact absorbed
None yet
None yet
Xeris Biopharma is seen as an exceptional opportunity after an earnings selloff, favored for its small-cap status and potential for undiscovered value.
Main discussion
Different voices
$XERS to day high and filling the gap created on that stupid selloff on the earnings report.
$XERS improved. The negative reaction to earnings was an exceptional opportunity.
$XERS $PGEN $STLN etc "This is why I favor smaller stocks. A small-cap with little or no analyst coverage is a place where a diligent individual can actually know something the market has not priced yet. The information is public, but almost no one has bothered to dig it out. Tha
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
